Voyager Therapeutics (VYGR)

Common Shares
Sell: $3.40|Buy: $3.64|Change: 0.06 (1.56%)

Company profile

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Address

75 Sidney Street
Cambridge
MA
USA
02139


Telephone

+1 857 2013463


Sector 

Healthcare


Previous key dates

NameKey Date
Voyager and KOL AD/PD™ 2025 Recap2025-04-07T16:30:00
Stifel 2025 Virtual CNS Forum2025-03-19T11:00:00
Voyager Therapeutics Inc Fourth Quarter Earnings Conference Call for 20242025-03-11T16:30:00
Voyager Therapeutics Inc Fourth Quarter Earnings Result for 20242025-03-11T00:00:00
Voyager Therapeutics Inc Annual Report for 20242025-03-11T00:00:00
TD Cowen 45th Annual Health Care Conference2025-03-03T13:50:00
Oppenheimer 25(th) Annual Healthcare Life Sciences Conference2025-02-11T14:40:00
Stifel 2024 Healthcare Conference2024-11-18T09:45:00
B. Riley Securities' Next-Gen Tissue Delivery Modalities Virtual Summit2024-11-14T13:30:00
Guggenheim Inaugural Healthcare Innovation Conference2024-11-13T14:00:00
Voyager Therapeutics Inc Third Quarter Earnings Conference Call for 20242024-11-12T16:30:00
Voyager Therapeutics Inc Third Quarter Earnings Result for 20242024-11-12T00:00:00
The Baird 2024 Global Healthcare Conference2024-09-11T13:25:00
The Wells Fargo 2024 Healthcare Conference2024-09-05T13:30:00
Voyager Therapeutics, Inc will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference2024-08-14T09:30:00
Voyager Therapeutics Inc Second Quarter Earnings Conference Call for 20242024-08-06T16:30:00
Voyager Therapeutics Inc Second Quarter Earnings Result for 20242024-08-06T00:00:00
H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference2024-06-27T07:00:00
TD Cowen Genetic Medicines & RNA Summit2024-06-20T13:35:00
Voyager Therapeutics Inc Annual General Meeting for 20242024-06-05T09:00:00
Voyager Therapeutics Inc First Quarter Earnings Conference Call for 20242024-05-13T16:30:00
Voyager Therapeutics Inc First Quarter Earnings Result for 20242024-05-13T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.